Assessing Health Outcomes for Women with Polycystic Ovary Syndrome and Hypertension

Introduction: The coexistence of hypertension (HTN) with polycystic ovary syndrome (PCOS) is prevalent and represents an extremely cardiometabolic risk in females. Purpose: The objective of this study was to evaluate cardiometabolic outcomes and quality of life among patients with PCOS and hypertension for 12 months. Methods: A cross-sectional study was carried out in different hospitals in Iraq. A total of 75 women with hypertension and PCOS during the period from May 2024 to May 2025 were studied. Baseline evaluation consisted of demographic characteristics, metabolic and clinical characterization, and phenotyping of PCOS. Patients were followed up for 12 months according to blood pressure control, metabolic data, treatment adherence (Morisky medication adherence scale), patient-oriented outcomes (SF-36), and side effects. Results: The cohort (mean age 32.4 ± 5.8 years) had a high baseline metabolic load; with mean BMI 34.1 kg/m ² and prevalent Dyslipidaemia (64.0%); insulin resistance (80.0%); Type 2 diabetes (25.3%); PCOS phenotype was the most frequent (60.0%); blood pressure control (<130/80 mmHg) at 12 months was reached in 37.3% of patients.; systolic BP (mean -12 mmHg, p<0.001); and HOMA-IR (median -0.5, (p=0.04) improved significantly, where greater adherence was associated with increased control rates of BP (54.3% vs. 22.5%, p=0.004) along with reduced hospital visits or ED visits (5.7% vs. 32.5%, p=0.003). Conclusion: our study indicates that PCOS women with PCOS and those with hypertension are at a high cardiometabolic risk profile, as well as have significant challenges in achieving guideline-recommended blood pressure.